LatestIP And Trademarks 7 October 2026
Poolbeg Pharma Secures South Korea Patent for POLB 001
Poolbeg Pharma secured a South Korean patent for its POLB 001 cancer immunotherapy candidate, adding to its growing global portfolio of patents related to cytokine release syndrome (CRS) in immunotherapy. The grant enhances the company’s IP strength and supports further development of the treatment.
Poolbeg Pharma has been granted a patent in South Korea for its POLB 001 cancer immunotherapy candidate. The approval expands the company’s international patent portfolio focused on cytokine release syndrome (CRS) associated with immunotherapy.
- Patent jurisdiction: South Korea
- Technology: POLB 001, targeting cancer immunotherapy‑related CRS
- Impact: Strengthens global IP position and supports future clinical development
Read the full announcement on Investing.com.
Need help understanding this update?
Connect with our domain experts instantly via WhatsApp for customized legal guidance.